However, with a fat increase of 0.40 kg
per year after tNRTI cessation, lipoatrophy may take over 5 years to resolve for many patients without additional intervention, at least for those with severe lipoatrophy [8]. Innovative antiretroviral MK2206 regimens using either new drugs (e.g. raltegravir or etravirine) or new treatment strategies (e.g. NRTI-sparing regimens) may warrant further evaluation in patients with severe lipoatrophy. The study was funded in part by educational grants from Abbott Laboratories and the Balnaves Foundation. The SHCS is financed in the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation. Andrew Carr is a recipient of selleck inhibitor a Practitioner Fellowship from the Australian National Health and Medical Research Council. The authors also wish to acknowledge John Ray, for measurement and validation of the uridine plasma concentrations; Nicole Easy, who performed the CT scans in Sydney; Sophie Zawadynski and Nick Pocock for DEXA scan validation; Matthew Law for statistical advice; and Danièle Scherrer and Linda Hotong for pharmacy assistance. Author contributions: Study concept and design: A. Calmy and A. Carr. Analysis
and interpretation of data: A. Calmy, A. Carr, C. Delhumeau, H. Wand, M. Bloch, B. Hirschel and R. Finlayson. Data extraction: H. Wand and C. Delhumeau. Drafting of the manuscript:
A. Calmy. Critical revision of the manuscript for important intellectual RG7420 chemical structure content: all authors. Statistical analysis: H. Wand and C. Delhumeau. Generation of allocation sequence and assignment of patients to their randomization groups: H. Wand (the randomization form had to be faxed to H. Wand, at the National Center for HIV Epidemiology and Research, and receipt of the randomization was provided within one working day). Study supervision: A. Carr. Financial disclosures A. Calmy, H. Wand, C. Delhumeau, R. Finlayson, M. Rafferty and R. Norris have no conflict of interest. B. Hirschel has received travel grants and speakers’ honoraria from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck Sharp & Dohme-Chibret and Roche. He also has participated in advisory boards for Merck, Tibotec and Pfizer. D. A. Cooper has received research funding from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck and Pfizer; consultancy fees and lecture and travel sponsorships from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck and Pfizer; and has served on advisory boards for Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck and Pfizer. A.